Influence of Pioglitazone for Renal Transplant Function in Diabetics

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test whether pioglitazone is able to prevent the progression of diabetic nephropathy in kidney transplant recipients with diabetes mellitus.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Technische Universität Dresden
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• kidney transplantation(> 6 months ago) ; stable graft function

• diabetes mellitus type 2

• acceptable glycemia (HbA1c < 8%)

• creatinin clearance (MDRD)>30 ml/min 1,73m²)

• proteinuria > 30 mg/24 hr

Exclusion Criteria:

• type 1 diabetes

• pregnant or breast feeding women

• congestive heart failure (>stage 1 NYHA)

• creeping creatinin

• treatment for rejection within 3 months prior to inclusion

• ALT, AST > 2.5 fold the upper limit of normal

• uncontrolled hypertension

• hypo- or hyperthyroidism